The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial

• Published in: British journal of cancer 2006-06, Vol.94 (11), p.1615-1620
• Main Authors: Al-Batran, S-E, Bischoff, J, von Minckwitz, G, Atmaca, A, Kleeberg, U, Meuthen, I, Morack, G, Lerbs, W, Hecker, D, Sehouli, J, Knuth, A, Jager, E
• Format: Article
• Language: English
• Subjects: Adult; Aged; Anthracyclines - therapeutic use; Antibiotics, Antineoplastic - therapeutic use; Antibiotics, Antineoplastic - toxicity; Biological and medical sciences; Biomedical and Life Sciences; Biomedicine; Breast Neoplasms - drug therapy; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Breast Neoplasms - surgery; Cancer Research; Clinical Study; Doxorubicin - analogs & derivatives; Doxorubicin - therapeutic use; Doxorubicin - toxicity; Drug Resistance; Epidemiology; Female; Gynecology. Andrology. Obstetrics; Humans; Mammary gland diseases; Medical sciences; Middle Aged; Molecular Medicine; Neoplasm Metastasis; Oncology; Polyethylene Glycols - therapeutic use; Polyethylene Glycols - toxicity; Survival Analysis; Treatment Outcome; Tumors
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/sj.bjc.6603158

This study evaluates the clinical benefit of pegylated liposomal doxorubicin (PLD) in patients with metastatic breast cancer (MBC), previously treated with conventional anthracyclines. Seventy-nine women with MBC previously treated with anthracyclines received PLD 50 mg m −2 every 4 weeks. All patients were previously treated with chemotherapy and 30% of patients had ⩾3 prior chemotherapies for metastatic disease. Patients were considered anthracycline resistant when they had disease progression on anthracycline therapy for MBC or within 6 months of adjuvant therapy. The overall clinical benefit rate (objective response+stable disease ⩾24 weeks) was 24% (16.1% in patients with documented anthracycline resistance vs 29% in patients classified as having non-anthracycline-resistant disease). There was no difference with respect to the clinical benefit between patients who received PLD >12 months and those who received PLD ⩽12 months since last anthracycline treatment for metastatic disease (clinical benefit 25 vs 24.1%, respectively). Median time to progression and overall survival were 3.6 and 12.3 months, respectively. The median duration of response was 12 months, and the median time to progression in patients with stable disease (any) was 9.5 months. Fourteen patients (17.7%) had a prolonged clinical benefit lasting ⩾12 months. In conclusion, PLD was associated with an evident clinical benefit in anthracycline-pretreated patients with MBC.